This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's (MRK) Keytruda Gets Full Approval for Bladder Cancer
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy, Keytruda, gets full approval from the FDA as a first-line treatment for bladder cancer, after having enjoyed accelerated approval for the indication.
Top Analyst Reports for Walmart, UnitedHealth & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), UnitedHealth Group Incorporated (UNH), and Starbucks Corporation (SBUX).
Merck's (MRK) VHL-Linked Tumor Drug Welireg Gets FDA Nod
by Zacks Equity Research
Merck's (MRK) Welireg (belzutifan) is the first and only systemic therapy approved for treating patients with certain types of von Hippel-Lindau (VHL) disease-associated tumors.
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda + partenr Eisai's Lenvima for advanced RCC in the first-line setting based on data from the phase III CLEAR/KEYNOTE-581 study.
mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally
by Indrajit Bandyopadhyay
Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.
Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA
by Zacks Equity Research
FDA likely to decide on Merck's (MRK) sBLA for Keytruda as an adjuvant therapy in certain patients with RCC on Dec 10 and in certain patients with MSI-H/dMMR advanced endometrial carcinoma on Mar 28, 2022.
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the second quarter. The company also lowers guidance for lead drug Tymlos.
Stock Market News for Aug 6, 2021
by Zacks Equity Research
Benchmarks ended in the green on Thursday, as investors accessed positive weekly jobless claims data and awaited the monthly jobs report on Aug 6.
Stock Market News for Aug 5, 2021
by Zacks Equity Research
The Dow and the S&P 500 closed in the red on Wednesday weighed by a lower-than-expected private-sector jobs report and Fed's Vice Chairman Richard Clarida's comment on higher interest rates in 2023 given the current path of economic recovery.
Amgen (AMGN) Q2 Earnings Top, COVID-Led Sales Woes to Linger
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It expects the pandemic to continue to hurt sales growth in the second half of 2021.
Stock Market News for Aug 4, 2021
by Zacks Equity Research
Benchmarks closed in the positive territory on Tuesday, as investors ignored the rise in new cases of the delta variant, and instead focused more on the upbeat second-quarter earnings results.
Amgen (AMGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 6.05% and 1.48%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Better-Than-Expected Earnings Push Pre-Markets Higher
by Zacks Equity Research
Better-Than-Expected Earnings Push Pre-Markets Higher
Stock Futures Indicate Higher Opening on Strong Q2 Earnings
by Zacks Equity Research
Stock futures rise in pre-market trade on impressive second-quarter earnings results.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More
by Kinjel Shah
Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.
AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised
by Zacks Equity Research
AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut
by Zacks Equity Research
Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.
Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust NASDAQ100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQEW